Pharma stocks climb up to 10.4 pc on FDI reforms

Image
Press Trust of India Mumbai
Last Updated : Jun 20 2016 | 8:42 PM IST
Pharma stocks today rose sharply by up to 10.4 per cent after the government today relaxed FDI norms for the sector.
Shares of Bliss GVS Pharma zoomed 10.44 per cent, Nectar Lifesciences soared 7.4 per cent and Sharon Bio-Medicine climbed 6.18 per cent on BSE.
The scrip of Fortis Healthcare rose by 1.86 per cent, Dr Reddys Lab (1.75 per cent) and Sun Pharma Advanced Research Company (1.74 per cent).
Government today launched a second wave of FDI reforms allowing 100 per cent inflows in civil aviation and food processing sectors while easing norms in defence and pharmaceuticals.
For the pharmaceuticals sector, the government relaxed the norms and permitted FDI up to 74 per cent through automatic route in brownfield projects and approval route beyond that limit to promote the development of this sector.
The move assumes significance as FDI in the existing pharma companies has been a contentious issue as concerns have been raised over some M&As of Indian pharma companies by foreign giants.
India is recognised as a major generic medicine hub of the world. The market size of the country's pharma industry is estimated at over USD 20 billion.
The government has also permitted 100 per cent FDI under automatic route in several wings of the broadcasting carriage services which include teleports, direct-to-home, cable networks, mobile TV and headend-in-the sky broadcasting service.
Shares of Den Networks rose by 2.99 per cent, Dish TV India was up 1.97 per cent and Sun TV Network gained 0.46 per cent on BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 20 2016 | 8:42 PM IST

Next Story